First-time anterior dislocation of the shoulder is associated with the development of recurrent instability. It is recognised that patients with recurrent instability often have osseous defects. Using 3D computerised tomography (3DCT) it is possible to quantify these defects. Whether these defects are present after the primary dislocation or occur progressively from multiple dislocations is unclear. We correlated the presence of Hill-Sachs lesions and anterior glenoid bone loss with evidence of recurrent dislocation and clinical outcomes. 78 patients were followed up for two years. All underwent a 3DCT within a week of injury. Standardised images of the humeral head and glenoid were produced. Using standardised digital techniques bone loss was measured. 39% of the patients developed further instability. Average Hill-Sachs circumferential length = 15.23%. Average Hill-Sachs surface area = 5.53%. The length and surface area of the Hill-Sachs lesions were significantly associated with further instability. (p=0.019 and p=0.003). Average en face glenoid surface area loss=1.30% with no association to instability (p=0.685). There was poor correlation between the size of the glenoid lesion and the size of the Hill-Sachs lesion. Results showed that age and increasing size of the Hill-Sachs lesions result in a higher rate of instability. Interestingly glenoid bone loss was relatively low and did not predict recurrent instability. The size of the Hill-Sachs lesion does not have a linear relationship with glenoid bone loss. Further work defining the morphology of the Hill-Sachs lesion and its engagement with a glenoid defect is required.
A Morton's neuroma is a painful forefoot disorder characterised by plantar pain and toe paraesthesia. Many treatments have been tried including modification of shoe wear, injections and surgery. The results from different treatment modalities are extremely variable in the scientific literature. We reviewed 79 patients who presented with an ultrasound proven Morton's Neuromata at an average of 60 months following treatment in a patient blind randomised trial. 35 had surgery with resection of the Morton's Neuromata. We compared the results of the patients who had had a steroid injection and surgery, a steroid injection alone, a placebo injection and then surgery and a placebo injection alone. We looked at the requirement for further consultations, pain scores, activity restrictions, footwear restriction, overall satisfaction with their treatment and overall quality of life scores. We found no significant difference between the groups. Overall 80% of the surgical patients had a good or excellent result and 67% of the non- operatively managed patients had a good or excellent result. There was no difference in their quality of life scores. Previous studies have shown little benefit in steroid injections in the treatment of Morton's Neuromata. We conclude at the five year mark there is no significant differences between operating on Morton's Neuromata and treating them conservatively. Further research should focus on comparing operative vs conservative treatment in the short to medium term. In order to justify the risks and costs of surgery.
At one year follow up functional testing was performed including range of movement. This tested for grip strength, multiple postional strengths and a functional score looking at activities of daily living.
We also showed that fractures that are most likely to malunite show a significantly poorer functional outcome and weaker grip strength.
In an age where patients and practitioners strive to ever increasing levels of knowledge this study allows us to counsel patients in their likely functional outcomes more accurately.
Despite increasing scientific investigation, the best method for preventing post-operative deep vein thrombosis remains unclear in patients undergoing a total hip replacement. In the wake of the recent controversial National Institute for Health and Clinical Excellence Clinical Guidelines on the prevention of thrombo-embolism, we felt it was timely to survey current Scottish Surgeons thrombo-prophylactic practice when performing total hip replacements. E-mail questionnaires were sent to all Scottish Orthopaedic consultants. They were asked about routine pharmacological and mechanical prophylaxis in patients undergoing total hip replacement. Comparison was made with a previous survey done in 2003. The response rate was 75%. The survey showed an increased use of pharmacological prophylaxis from 93% to 100%. This was due to the increased use of aspirin, from 51% to 64%. The use of Low molecular weight heparin had remained the same at 51%. No surgeons routinely use Warfarin, low dose heparin or Fondaparinux. Use of graded compression stockings has increased from 59% to 70%. There is increasing evidence that patients undergoing total hip replacement should receive extended prophylaxis for up to 35 days. This could explain why aspirin is commonly used. Most guidelines, however, do not recommend this drug. With the recent launch of two new oral agents we may see a huge change in prophylaxis in Scotland, as 94% of surgeons said they would use extended prophylaxis if a safe oral agent was found.
Our aim was to determine the exactly whether bone incorporation may be correctly assessed by this method by comparing the results to those obtained by spiral CT imaging.
Outcome measures included rate of complications: infection, DVT, PE, length of hospital stay and Harris Hip Score (HHS). Statistical analysis was undertaken to determine any correlation between smoking and these outcome measures using chi-squared tests, t-tests and multiple regression adjusting for confounding factors.
268 patients (15%) were smokers, 582 patients (33%) were ex-smokers and 917 patients (52%) had never smoked. As there was little data available on when the ex-smokers had stopped smoking we studied current smokers compared to patients that had never smoked There were no significant differences in complications such as DVT, PE, Deep infection and Superficial infection, these were all rare events. Neither was there any significant difference in hospital stay times. After adjusting for pre-operative HHS, age, sex and ASA status current smokers had significantly lower HHS at 6 months (p<
0.001, 95% confidence interval for effect size 1.6 to 5.3), and also showed a lower HHS at 18 months, 3 years and 5 years although not significantly so.
We plan to further analysis the data to try and ascertain why this is the case.